GLP-1争霸,前三季度诺和诺德暂时领先,但优势只有6亿美元

每日经济新闻
Yesterday

每经记者|陈星 每经编辑|陈俊杰糖尿病与减肥药物市场的竞争从未像今天这样激烈,两款GLP-1类药物——诺和诺德的司美格鲁肽与礼来的替尔泊肽正围绕全球“药王”宝座展开激烈争夺。11月5日,诺和诺德公布2025年第三季度业绩,最受外界关注的司美格鲁肽产品线依然保持增长,前三季度总计销售额达到254.62亿美元,同比增长24%。而根据礼来此前公布的三季报,替尔泊肽前三季度实现销售额248.37...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10